Chelsea Counsel Co. Sells 6,887 Shares of Solventum Corporation $SOLV

Chelsea Counsel Co. trimmed its holdings in shares of Solventum Corporation (NYSE:SOLV) by 77.3% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,023 shares of the company’s stock after selling 6,887 shares during the period. Chelsea Counsel Co.’s holdings in Solventum were worth $160,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Mitsubishi UFJ Asset Management Co. Ltd. lifted its holdings in Solventum by 15.3% in the third quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 307,789 shares of the company’s stock valued at $22,469,000 after acquiring an additional 40,812 shares during the period. Davis Selected Advisers grew its stake in shares of Solventum by 0.5% during the 3rd quarter. Davis Selected Advisers now owns 5,517,611 shares of the company’s stock valued at $402,786,000 after purchasing an additional 24,950 shares during the period. Appleton Partners Inc. MA purchased a new stake in shares of Solventum during the 4th quarter valued at about $7,008,000. Vanguard Group Inc. lifted its stake in shares of Solventum by 5.3% in the 3rd quarter. Vanguard Group Inc. now owns 17,121,198 shares of the company’s stock worth $1,249,847,000 after purchasing an additional 867,837 shares during the period. Finally, SG Americas Securities LLC lifted its stake in shares of Solventum by 92.3% in the 4th quarter. SG Americas Securities LLC now owns 93,681 shares of the company’s stock worth $7,423,000 after purchasing an additional 44,970 shares during the period.

Analysts Set New Price Targets

Several analysts recently issued reports on the stock. Rothschild & Co Redburn started coverage on shares of Solventum in a research report on Tuesday, March 24th. They set a “sell” rating and a $60.00 target price for the company. UBS Group downgraded shares of Solventum from a “buy” rating to a “neutral” rating and set a $50.00 price target on the stock. in a research report on Thursday, May 14th. Wells Fargo & Company dropped their price target on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. KeyCorp boosted their price objective on shares of Solventum from $92.00 to $93.00 and gave the company an “overweight” rating in a research report on Wednesday, May 6th. Finally, Wall Street Zen lowered Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. Eight research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $84.25.

Solventum Trading Up 1.6%

Solventum stock opened at $75.72 on Friday. Solventum Corporation has a 12-month low of $62.38 and a 12-month high of $88.20. The firm has a market capitalization of $13.11 billion, a price-to-earnings ratio of 9.28, a P/E/G ratio of 1.15 and a beta of 0.69. The firm has a 50 day moving average of $73.51 and a 200 day moving average of $74.94. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96.

Solventum (NYSE:SOLV) last issued its quarterly earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same quarter in the previous year, the firm earned $1.34 earnings per share. The company’s revenue for the quarter was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. As a group, research analysts predict that Solventum Corporation will post 6.58 earnings per share for the current year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.